Library

Adverse Effects of Vaccines / Kathleen Stratton / Washington, D.C. : National Academy Press (2011)  

Adverse Effects of Vaccines : Evidence and Causality [printed text] / Kathleen Stratton, Author ; Andrew Ford, Author ; Erin Rusch, Author ; Ellen Wright Clayton, Author . - Washington, D.C. : National Academy Press, 2011 . - 800 p. : ill. ; A5. ISBN : 978-0-309-21435-3 : $ 72,86 Languages : English (eng) Descriptors: Indexation Electronic books ; Encephalitis, Varicella Zoster ; Epidemiology ; Evidence-Based Practice ; Influenza Vaccines ; Papillomavirus Vaccines ; United States ; Vaccines Classification QW 805 Vaccines. Antitoxins. Toxoids Abstract: In 1900, for every 1000 babies born in the United States, 100 would die before their first birthday, often due to infectious diseases. Today, vaccines exist for many viral and bacterial diseases. The cornerstone of the vaccine safety system in the United States is the National Childhood Vaccine Injury Act. This legislation was intended to bolster vaccine research and development through federal coordination of vaccine initiatives, and by providing relief to vaccine manufacturers facing financial burdens. A key component of the legislation required the Department of Health and Human Services to collaborate with the Institute of Medicine to assess concerns about the safety of vaccines and potential adverse effects, especially in children. The Adverse Effects of Vaccines reviews the epidemiological, clinical, and biological evidence regarding adverse health effects associated with specific vaccines covered by the Vaccine Injury Compensation Program including varicella zoster vaccine, influenza vaccines, hepatitis B vaccine, and the human papillomavirus vaccine, among others. For each possible adverse event, the report reviews prior studies, summarizes their findings, and evaluates the epidemiological evidence. It finds that while no vaccine is 100% safe, very few adverse events are shown to be caused by vaccines. In addition, the evidence shows that vaccines do not cause several conditions of recent concern. For example, the MMR vaccine is not associated with autism or childhood diabetes. The DTaP vaccine is also not associated with diabetes and the influenza vaccine given as a shot does not exacerbate asthma. The Adverse Effects of Vaccines will be of special interest to the National Vaccine Program Office, the Centers for Disease Control and Prevention, vaccine safety researchers and manufacturers, parents, caregivers, and health professionals in the private and public sectors. Contents note: SUMMARY 1 -- Charge to the Committee 2 -- Assessing the Weight of Evidence 2 -- Causality Assessment 5 -- Causality Conclusions 7 -- Susceptibility 9 -- Concluding Comment 9 -- References 24 -- 1 INTRODUCTION 25 -- Charge to the Committee 27 -- Committee Process 28 -- Outline of the Report 28 -- References 33 -- 2 APPROACH 35 -- Literature Searching 35 -- Weight of Evidence 36 -- Causality Assessment 41 -- Special Considerations 45 -- References 48 -- 3 EVALUATING BIOLOGICAL MECHANISMS OF ADVERSE EVENTS 51 -- Latency Between Antigen Exposure and Peak Adaptive Immune Response 51 -- Immune-Mediated Mechanisms 52 -- Viral Activity 66 -- Injection-Related Adverse Events 67 -- Coagulation and Hypercoagulable States 69 -- Increased Susceptibility 70 -- Alterations in Brain Development 73 -- Contribution of Animal Models 76 -- References 79 -- 4 MEASLES, MUMPS, AND RUBELLA VACCINE 89 -- Introduction 89 -- Measles Inclusion Body Encephalitis 93 -- Encephalitis and Encephalopathy 95 -- Febrile Seizures 100 -- Afebrile Seizures 105 -- Meningitis 107 -- Ataxia 110 -- Autism 112 -- Acute Disseminated Encephalomyelitis 115 -- Transverse Myelitis 116 -- Optic Neuritis 117 -- Neuromyelitis Optica 119 -- Multiple Sclerosis Onset in Adults 120 -- Multiple Sclerosis Onset in Children 122 -- Guillain-Barré Syndrome 123 -- Chronic Inflammatory Disseminated Polyneuropathy 124 -- Opsoclonus Myoclonus Syndrome 125 -- Brachial Neuritis 125 -- Anaphylaxis 126 -- Transient Arthralgia in Women 130 -- Transient Arthralgia in Children 134 -- Chronic Arthralgia in Women 137 -- Chronic Arthritis in Women 140 -- Chronic Arthropathy in Children 143 -- Arthropathy in Men 144 -- Type 1 Diabetes 146 -- Hepatitis 149 -- Chronic Fatigue Syndrome 150 -- Fibromyalgia 151 -- Hearing Loss 151 -- References 196 -- 5 VARICELLA VIRUS VACCINE 211 -- Introduction 211 -- Disseminated Oka VZV Without Other Organ Involvement 213 -- Disseminated Oka VZV with Other Organ Involvement 219 -- Vaccine Strain Viral Reactivation Without Other Organ Involvement 224 -- Vaccine Strain Viral Reactivation with Other Organ Involvement 228 -- Encephalopathy 233 -- Seizures 233 -- Cerebellar Ataxia 235 -- Acute Disseminated Encephalomyelitis 236 -- Transverse Myelitis 237 -- Guillain-Barré Syndrome 238 -- Small Fiber Neuropathy 239 -- Anaphylaxis 239 -- Onset or Exacerbation of Arthropathy 242 -- Stroke 243 -- Thrombocytopenia 244 -- References 248 -- 6 INFLUENZA VACCINE 257 -- Introduction 257 -- Encephalitis and Encephalopathy 262 -- Seizures 264 -- Acute Disseminated Encephalomyelitis 267 -- Optic Neuritis 269 -- Neuromyelitis Optica 271 -- Multiple Sclerosis Onset in Adults 271 -- Multiple Sclerosis Relapse in Adults 273 -- Guillain-Barré Syndrome 275 -- Chronic Inflammatory Disseminated Polyneuropathy 281 -- Bell’s Palsy 282 -- Brachial Neuritis 284 -- Small Fiber Neuropathy 285 -- Anaphylaxis 285 -- Inactivated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children and Adults 288 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Children Younger Than 5 Years of Age 293 -- Live Attenuated Influenza Vaccine and Asthma Exacerbation or Reactive Airway Disease -- Episodes in Persons 5 Years of Age or Older 298 -- Onset or Exacerbation of Systemic Lupus Erythematosus 301 -- Onset or Exacerbation of Vasculitis 304 -- Polyarteritis Nodosa 306 -- Onset or Exacerbation of Arthropathy 307 -- Stroke 308 -- Myocardial Infarction 309 -- Fibromyalgia 311 -- All-Cause Mortality 311 -- Oculorespiratory Syndrome 313 -- References 354 -- 7 HEPATITIS A VACCINE 369 -- Introduction 369 -- Acute Disseminated Encephalomyelitis 370 -- Transverse Myelitis 371 -- Multiple Sclerosis 372 -- Guillain-Barré Syndrome 373 -- Chronic Inflammatory Disseminated Polyneuropathy 374 -- Bell’s Palsy 374 -- Anaphylaxis 375 -- Autoimmune Hepatitis 376 -- References 378 -- 8 HEPATITIS B VACCINE 381 -- Introduction 381 -- Encephalitis and Encephalopathy 383 -- Seizures 383 -- Acute Disseminated Encephalomyelitis 385 -- Transverse Myelitis 386 -- Optic Neuritis 387 -- Neuromyelitis Optica 389 -- Multiple Sclerosis Onset in Adults 390 -- Multiple Sclerosis Onset in Children 392 -- Multiple Sclerosis Relapse in Adults 394 -- Multiple Sclerosis Relapse in Children 395 -- First Demyelinating Event in Adults 396 -- First Demyelinating Event in Children 399 -- Guillain-Barré Syndrome 400 -- Chronic Inflammatory Disseminated Polyneuropathy 401 -- Brachial Neuritis 402 -- Anaphylaxis 402 -- Erythema Nodosum 403 -- Onset or Exacerbation of Systemic Lupus Erythematosus 404 -- Onset or Exacerbation of Vasculitis 406 -- Onset or Exacerbation of Polyarteritis Nodosa 409 -- Onset or Exacerbation of Psoriatic Arthritis 411 -- Onset or Exacerbation of Reactive Arthritis 412 -- Onset or Exacerbation of Rheumatoid Arthritis 414 -- Onset or Exacerbation of Juvenile Idiopathic Arthritis 416 -- Type 1 Diabetes 418 -- Fibromyalgia 420 -- References 431 -- 9 HUMAN PAPILLOMAVIRUS VACCINE 441 -- Introduction 441 -- Acute Disseminated Encephalomyelitis 442 -- Transverse Myelitis 443 -- Neuromyelitis Optica 444 -- Multiple Sclerosis 444 -- Guillain-Barré Syndrome 445 -- Chronic Inflammatory Disseminated Polyneuropathy 446 -- Brachial Neuritis 447 -- Amyotrophic Lateral Sclerosis 447 -- Anaphylaxis 449 -- Transient Arthralgia 450 -- Pancreatitis 451 -- Thromboembolic Events 452 -- Hypercoagulable States 453 -- References 455 -- 10 DIPHTHERIA TOXOID-, TETANUS TOXOID-, AND ACELLULAR PERTUSSISCONTAINING -- VACCINES 457 -- Introduction 457 -- Encephalitis and Encephalopathy 461 -- Infantile Spasms 464 -- Seizures 465 -- Ataxia 468 -- Autism 468 -- Acute Disseminated Encephalomyelitis 469 -- Transverse Myelitis 470 -- Optic Neuritis 471 -- Multiple Sclerosis Onset in Adults 472 -- Multiple Sclerosis Relapse in Adults 474 -- Multiple Sclerosis Relapse in Children 476 -- Guillain-Barré Syndrome 477 -- Chronic Inflammatory Disseminated Polyneuropathy 478 -- Opsoclonus Myoclonus Syndrome 480 -- Bell’s Palsy 480 -- Anaphylaxis 482 -- Chronic Urticaria 483 -- Serum Sickness 484 -- Arthropathy 485 -- Type 1 Diabetes 487 -- Myocarditis 490 -- Fibromyalgia 491 -- Sudden Infant Death Syndrome 491 -- Immune Thrombocytopenic Purpura 492 -- References 506 -- 11 MENINGOCOCCAL VACCINE 515 -- Introduction 515 -- Encephalitis and Encephalopathy 517 -- Acute Disseminated Encephalomyelitis 518 -- Transverse Myelitis 519 -- Multiple Sclerosis 519 -- Guillain-Barré Syndrome 520 -- Chronic Inflammatory Disseminated Polyneuropathy 521 -- Anaphylaxis 522 -- Chronic Headache 523 -- References 526 -- 12 INJECTION-RELATED ADVERSE EVENTS 529 -- Complex Regional Pain Syndrome 529 -- Deltoid Bursitis 531 -- Syncope 533 -- References 538 -- 13 CONCLUDING COMMENTS 541 -- References 545 Link for e-copy: http://www.nap.edu/catalog.php?record_id=13164 Format of e-copy: PDF [Open Access] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2712

Analyse coût-efficacité de la vaccination des garçons contre le virus HPV / Nancy Thiry / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)  

Analyse coût-efficacité de la vaccination des garçons contre le virus HPV : Synthèse [printed text] / Nancy Thiry, Author ; Sophie Gerkens , Author ; Justien Cornelis , Author ; Vicky Jespers , Author ; Germaine Hanquet, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2019 . - 21 p. : ill., ; A4. - (KCE Reports B. Health Technology Assessment (HTA); 308B) . ISSN : D/2019/10.273/12 : € 0,00 Languages : French (fre) Descriptors: Indexation 2017-04 ; Costs and Cost Analysis ; Female ; Male ; Papillomavirus Infections ; Papillomavirus Vaccines ; R308 ; Technology Assessment, Biomedical Classification QZ 204 Precancerous conditions. Tumor virus infections Abstract: Le vaccin contre le papillomavirus humain (HPV) responsable du cancer du col de l’utérus est introduit depuis une petite dizaine d’années dans notre pays, mais seules les filles en bénéficient. Or il est désormais établi que ce même virus est également impliqué dans d’autres cancers, dont celui de la gorge. Les recommandations ont donc été revues et, dans la plupart des pays occidentaux comme chez nous, il est désormais conseillé de vacciner les garçons aussi. La question de l’impact clinique et économique d’une telle extension des programmes de vaccination a donc été posée au Centre fédéral d’Expertise des Soins de Santé (KCE), qui publie aujourd’hui une étude favorable. Contents note: PRÉFACE. 1 -- SYNTHÈSE . 2 -- TABLE DES MATIÈRES. 2 -- 1. CONTEXTE. 4 -- 1.1. LE VIRUS HPV ET LE RISQUE DE CANCER 4 -- 1.2. LES VACCINS ANTI-HPV 4 -- 1.3. LA VACCINATION ANTI-HPV EN BELGIQUE . 6 -- 1.4. QUESTIONS DE RECHERCHE 7 -- 2. MORBIDITÉ ET MORTALITÉ DU HPV EN BELGIQUE. 8 -- 2.1. CANCERS LIÉS AU HPV. 8 -- 2.2. DESCRIPTION PAR TYPE DE CANCER. 10 -- 2.2.1. Cancers du col utérin 10 -- 2.2.2. Cancers de l’anus 10 -- 2.2.3. Cancers de la vulve 10 -- 2.2.4. Cancers du vagin 10 -- 2.2.5. Cancers du pénis 11 -- 2.2.6. Cancers de l’oro-pharynx 11 -- 2.3. VERRUES ANO-GÉNITALES. 11 -- 2.4. AUTRES COMPLICATIONS DE L’INFECTION PAR HPV 11 -- 2.5. DIFFÉRENCES HOMMES-FEMMES DANS LES AFFECTIONS LIÉES AU HPV 12 -- 3. EFFICACITÉ ET SÉCURITÉ DES VACCINS. 12 -- 3.1. EFFICACITÉ. 12 -- 3.2. PROTECTION CROISÉE 13 -- 3.3. DURÉE DE LA PROTECTION13 -- 3.4. SÉCURITÉ. 13 -- 3.5. EFFET INDIRECT . 14 -- 4. VACCINATION DES GARÇONS DANS D’AUTRES PAYS INDUSTRIALISÉS.14 -- 5. ANALYSE ÉCONOMIQUE 16 -- 5.1. QUEL SERAIT LE RAPPORT COUT-EFFICACITE D’UNE VACCINATION UNIVERSELLE (FILLES ET GARÇONS) PAR RAPPORT A LA VACCINATION DES FILLES SEULES, DANS LES « INDICATIONS EMA » ? 17 -- 5.1.1. Pour une couverture des filles similaire à celle de la Communauté flamande 17 -- 5.1.2. Pour une couverture des filles similaire à celle de la Fédération Wallonie-Bruxelles 17 -- 5.2. QUEL SERAIT LE RAPPORT COÛT-EFFICACITÉ D’UNE VACCINATION UNIVERSELLE PAR RAPPORT À LA VACCINATION DES FILLES SEULES, POUR PROTÉGER CONTRE TOUTES LES AFFECTIONS LIÉES AU HPV ? . 18 -- 5.2.1. Pour une couverture des filles similaire à celle de la Communauté flamande 18 -- 5.2.2. Pour une couverture des filles similaire à celle de la Fédération Wallonie-Bruxelles 18 -- 5.3. EST-CE QU’UNE AUGMENTATION DE LA COUVERTURE VACCINALE CHEZ LES FILLES -- SEULES SERAIT PLUS COÛT-EFFICACE QUE L'EXTENSION DU VACCIN AUX GARÇONS? 18 -- 5.4. SI LA VACCINATION UNIVERSELLE EST CHOISIE, QUEL SERAIT LE VACCIN LE PLUS COÛTEFFICACE ?. 19 -- 5.5. QUEL SERAIT LE RAPPORT COÛT-EFFICACITÉ DE LA VACCINATION UNIVERSELLE PAR RAPPORT À CELLE DES FILLES SEULES AVEC DES PRIX DE VACCIN BAS ? 19 -- 5.6. QUEL EST L'IMPACT DE LA DURÉE DE PROTECTION DU VACCIN SUR LE RAPPORT COÛTEFFICACITÉ ?. 19 -- 5.7. QUESTIONS AUXQUELLES CETTE ÉTUDE N’A PAS PU RÉPONDRE 19 -- 6. CONCLUSION 20 Link for e-copy: https://kce.fgov.be/pdf/308Bs Format of e-copy: PDF (1,31 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4510

Cost-effectiveness analysis of HPV vaccination of boys in Belgium / Nancy Thiry / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)  

Cost-effectiveness analysis of HPV vaccination of boys in Belgium [printed text] / Nancy Thiry, Author ; Sophie Gerkens , Author ; Justien Cornelis , Author ; Vicky Jespers , Author ; Germaine Hanquet, Author . - Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre, 2019 . - 107 p. : ill., ; A4. - (KCE Reports. Health Technology Assessment (HTA); 308) . ISSN : D/2019/10.273/13 : € 0,00 Languages : English (eng) Descriptors: Indexation 2017-04 ; Costs and Cost Analysis ; Female ; Male ; Papillomavirus Infections ; Papillomavirus Vaccines ; R308 ; Technology Assessment, Biomedical Classification QZ 204 Precancerous conditions. Tumor virus infections Contents note: LIST OF FIGURES 4 -- LIST OF TABLES .5 -- LIST OF ABBREVIATIONS 7 -- SCIENTIFIC REPORT .9 -- 1 BACKGROUND .9 -- 1.1 HPV INFECTION AND DISEASE .9 -- 1.2 THE HPV VACCINES 10 -- 1.2.1 Cervarix .11 -- 1.2.2 Gardasil .11 -- 1.2.3 Gardasil 9 .12 -- 2 HPV VACCINATION IN BELGIUM 12 -- 2.1 RECOMMENDATIONS OF HPV VACCINATION 12 -- 2.2 ORGANISATION AND FUNDING 13 -- 2.2.1 NIHDI reimbursement 13 -- 2.2.2 Vaccination programmes .14 -- 2.3 VACCINE UPTAKE 14 -- 3 RESEARCH QUESTIONS .15 -- 4 BURDEN OF HPV DISEASES IN BELGIUM 17 -- 4.1 METHODS 17 -- 4.2 HPV PREVALENCE IN BELGIUM OR IN SIMILAR SETTINGS 17 -- 4.3 BURDEN OF HPV-RELATED CANCERS .18 -- 4.3.1 Cervical cancer .22 -- 4.3.2 Anal cancers 22 -- 4.3.3 Vulvar cancer .22 -- 4.3.4 Vaginal cancer 23 -- 4.3.5 Penile cancer .23 -- 4.3.6 Oropharyngeal cancers .24 -- 4.4 BURDEN OF ANOGENITAL WARTS 25 -- 4.5 OTHER COMPLICATIONS OF HPV INFECTION .26 -- 4.6 GENDER DIFFERENCES IN HPV-RELATED DISEASES 26 -- 5 VACCINE EFFICACY AND SAFETY 27 -- 5.1 METHODS 27 -- 5.2 VACCINE EFFICACY 27 -- 5.2.1 Cervical cancers 29 -- 5.2.2 Anal cancer .31 -- 5.2.3 Vulvar and vaginal cancers .32 -- 5.2.4 Penile cancer .33 -- 5.2.5 Oropharyngeal cancer 34 -- 5.2.6 Anogenital warts 35 -- 5.2.7 Additional results for HPV9 .36 -- 5.3 BRIDGING STUDIES 36 -- 5.4 CROSS-PROTECTION 36 -- 5.5 DURATION OF PROTECTION 37 -- 5.6 EFFICACY OF SHORTER SCHEDULE .37 -- 5.7 COMPARISON ACROSS VACCINES .38 -- 5.8 VACCINE SAFETY .38 -- 6 HERD EFFECTS OF HPV VACCINATION 39 -- 6.1 METHODS 39 -- 6.2 SYSTEMATIC REVIEWS 39 -- 6.3 AUSTRALIA 40 -- 7 HPV VACCINATION OF MALES IN OTHER INDUSTRIALISED COUNTRIES 41 -- 7.1 BOYS .41 -- 7.2 MEN HAVING SEX WITH MEN 44 -- 8.1 METHODS 45 -- 8.2. Technical characteristics, vaccine costs and diseases modelled 46 -- 8.2.2 Vaccine efficacy and duration of protection 48 -- 8.2.3 Outcomes considered 50 -- 8.2.4 Disease burden and HPV attribution fraction .50 -- 8.3.1 Criteria 55 -- 8.3.2 Results 55 -- 8.4.1 What is the cost-effectiveness universal (girls and boys) versus girl-only HPV vaccination for the EMA+ indications? 59 -- 8.4.2 What is the cost-effectiveness of universal (girls and boys) versus girl-only HPV vaccination for all HPV-related diseases? 63 -- 8.4.3 Is extending HPV vaccination to boys more cost-effective than increasing the vaccine uptake in girls? 66 -- 8.4.4 If universal (girls and boys) vaccination is opted for, which vaccine is cost-effective? 68 -- 8.4.5 What is the cost-effectiveness of universal (girls and boys) versus girl-only vaccination using low vaccine prices? 69 -- 8.4.6 What is the impact of the vaccine duration of protection on the incremental costeffectiveness ratio? .70 -- 9 DISCUSSION 72 -- 9.1 CLINICAL ASPECTS .72 -- 9.2 ECONOMIC ASPECTS 73 -- 9.3 OTHER ASPECTS 74 -- 9.4 LIMITATIONS 75 -- 9.5 CONCLUSIONS 76 -- APPENDICES 77 -- REFERENCES .94 Link for e-copy: http://kce.fgov.be/pdf/308C Format of e-copy: PDF (3,02 Mb) Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=4509

Cost-effectiveness of human papillomavirus vaccination in Belgium / Nancy Thiry in International Journal of Technology Assessment in Health Care, 25(2009)2 ([04/01/2009])  

[article] Cost-effectiveness of human papillomavirus vaccination in Belgium : do not forget about cervical cancer screening [printed text] / Nancy Thiry, Author ; Chris De Laet , Author ; Frank Hulstaert, Author ; Mattias Neyt , Author ; Huybrechts, Michel, Author ; Irina Cleemput , Author . - 2009 . - 161-170. Languages : English (eng) in International Journal of Technology Assessment in Health Care > 25(2009)2 [04/01/2009] . - 161-170 Descriptors: Classification W 1 Serials. Periodicals Indexation 2007-13 ; Adolescent ; Adult ; Belgium ; Child ; Cohort Studies ; Cost-Benefit Analysis ; Female ; Great Britain ; Health Care Costs ; Humans ; Journal Article ; Markov Chains ; Mass Screening ; Papillomavirus Vaccines ; Peer Review ; Quality-Adjusted Life Years ; R64 ; Uterine Cervical Neoplasms ; Vaccination Abstract: OBJECTIVES: The cost-effectiveness of adding a human papillomavirus (HPV) vaccination program in 12-year-old females to the recommended cervical cancer screening in Belgium is examined. Moreover, the health and economic consequences of a potential decline in screening uptake after initiation of a HPV vaccination program are investigated. METHODS: A static Markov model is developed to estimate the direct effect of vaccination on precancerous lesions and cervical cancers. RESULTS: Vaccination is estimated to avoid 20 percent of the cervical cancers occurring in a 12-year-old girls' cohort and to cost 32,665 euro per quality-adjusted life-year (QALY) gained (95 percent credibility interval [CrI]: 17,447 euro to 68,078 euro), assuming a booster injection after 10 years, a limited duration of protection and discounting costs and effects at 3 percent and 1.5 percent, respectively. Assuming lifelong protection, HPV vaccination is estimated to cost 14,382 euro (95 percent CrI: 9,238 euro to 25,644 euro) per QALY gained, while avoiding 50 percent of the cervical cancer cases. In the base-case, a 10 percent reduction in screening compliance after vaccination obliterates the effect of vaccination on cervical cancer cases avoided, whereas further declines in the level of screening compliance even turned out to be detrimental for the cohort's health, inducing a mean loss in QALYs and life-year gained compared with the situation prevaccination. CONCLUSIONS: An HPV vaccination program should only be considered if the level of screening after vaccination can be maintained. Link for e-copy: http://doi.org/10.1017/S0266462309090217 Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2200 [article]

How many CIN2+ lesions can be avoided through HPV 16/18 vaccination? / Frank Hulstaert in Acta obstetricia et gynecologica Scandinavica, 88(2009)07 ([07/01/2009])  

[article] How many CIN2+ lesions can be avoided through HPV 16/18 vaccination? [printed text] / Frank Hulstaert, Author ; Chris De Laet , Author . - 2009 . - 859. Languages : English (eng) French (fre) German (ger) in Acta obstetricia et gynecologica Scandinavica > 88(2009)07 [07/01/2009] . - 859 Descriptors: Classification W 1 Serials. Periodicals Indexation Cervical Intraepithelial Neoplasia ; Cervix Uteri ; Female ; Great Britain ; Gynecologic Surgical Procedures ; Humans ; Journal Article ; Papillomavirus Infections ; Papillomavirus Vaccines ; Peer Review ; Premature Birth Link for e-copy: http://informahealthcare.com/doi/full/10.1080/00016340902989005?prevSearch=allfi [...] Format of e-copy: PDF [Requires Subscription] Record link: https://kce.docressources.info/index.php?lvl=notice_display&id=2199 [article]

HPV Vaccinatie ter Preventie van Baarmoederhalskanker in België. HTA / Nancy Thiry ; Marie-Laurence Lambert ; Irina Cleemput ; Huybrechts, Michel ; Mattias Neyt ; Frank Hulstaert ; Chris De Laet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)  

Permalink

HPV Vaccination for the Prevention of Cervical Cancer in Belgium: HTA / Nancy Thiry ; Marie-Laurence Lambert ; Irina Cleemput ; Huybrechts, Michel ; Mattias Neyt ; Frank Hulstaert ; Chris De Laet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)  

Permalink

Kosteneffectiviteitsanalyse van een vaccinatie van jongens tegen het HPV-virus / Nancy Thiry / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2019)  

Permalink

Vaccination HPV pour la prévention du cancer du col de l'utérus en Belgique: HTA / Nancy Thiry ; Marie-Laurence Lambert ; Irina Cleemput ; Huybrechts, Michel ; Mattias Neyt ; Frank Hulstaert ; Chris De Laet / Brussels [Belgium] : KCE = Federaal Kenniscentrum voor de Gezondheidszorg = Centre Fédéral d'Expertise des Soins de Santé = Belgian Health Care Knowledge Centre (2007)  

Permalink